Anti-PD-L1 combinations for treating tumors

1. A method of treating a cancer or a tumor comprising, a step of administering to a human patient in need thereof, a combination consisting of:

(i) a pharmaceutical composition consisting of an effective amount of 1) a PD-L/PD-1 Axis antagonist antibody or functional fragment thereof, wherein said PD-L/PD-1 Axis antagonist antibody is selected from the group consisting of a PD-1 binding antagonist and a PD-L1 binding antagonist and 2) one or more pharmaceutically acceptable carriers, excipients, or diluents;

(ii) a pharmaceutical composition consisting of 1) an effective amount of a immunotherapeutic, wherein the immunotherapeutic is 4-amino-2-(ethoxymethyl)-a,a-di-methyl-1H-imidazo[4,5-c]quinoline-1-ethanol and 2) one or more pharmaceutically acceptable carriers, excipients, or diluents; and optionally,

(iii) an effective amount of an additional therapeutic agent, wherein the additional therapeutic agent is an anticancer agent selected from the group consisting of a chemotherapeutic agent, an antimetabolite, an inhibitor of topoisomerase I and II, an alkylating agent, a microtubule inhibitor, an antiandrogen agent, a GNRh modulator or mixtures thereof;

wherein the immunotherapeutic is administered intravenously at a weekly dose of from about 0.007 mg/kg to about 0.02 mg/kg;

wherein the PD-L/PD-1 Axis antagonist antibody and the immunotherapeutic are not covalently linked to each other; and

wherein the efficacy of the combination is enhanced as compared to that of the PD-L/PD-1 Axis antagonist or immunotherapeutic alone.

2. The method of claim 1 , wherein the PD-L/PD-1 Axis antagonist is a PD-1 binding antagonist.

3. The method of claim 2 , wherein the PD-1 binding antagonist is a full-length antibody.

4. The method of claim 3 , wherein the PD-1 binding antagonist is MDX-1106, Merck 3475, CT-011, AMP-224, or AMP-514.

5. The method of claim 1 , wherein the PD-L/PD-1 Axis antagonist is a PD-L1 binding antagonist.

6. The method of claim 5 , wherein the PD-L1 binding antagonist is a full-length antibody.

7. The method of claim 6 , wherein the PD-L1 binding antagonist is selected from the group consisting of: YW243.55.S70, MPDL3280A, MDX-1105, MEDI-4736, and MSB0010718C.

8. The method of claim 1 , comprising administering the anticancer agent.

9. The method of claim 8 , wherein said anticancer agent is a chemotherapeutic agent selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, imatanib, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, cytarabine, 5- fluorouracil, methotrexate, docetaxel, goserelin, vincristine, vinblastine, nocodazole, teniposide etoposide, gemcitabine, epothilone, vinorelbine, camptothecin, daunorubicin, actinomycin D, mitoxantrone, acridine, doxorubicin, epirubicin, or idarubicin.

10. The method of claim 1 , wherein said cancer is selected from the group consisting of: breast cancer, colorectal cancer, diffuse large B-cell lymphoma, endometrial cancer, follicular lymphoma, gastric cancer, glioblastoma, head and neck cancer, hepatocellular cancer, lung cancer, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, and renal cell carcinoma.

11. The method of claim 1 , wherein said immunotherapeutic in said subject has a local concentration that is from about 0.005 μg/ml to about 12 μg/ml.

12. The method of claim 1 , wherein said immunotherapeutic in said subject has a local concentration that is from about 0.05 μg/ml, 0.1 μg/ml, 0.15 μg/ml, 0.2 μg/ml, 0.3 μg/ml, or 0.4 μg/ml, to about 0.5 μg/ml.